Personalised cancer vaccines: A major breakthrough in cancer treatment
Personalised cancer vaccines are emerging as one of the most exciting developments in modern cancer research. They represent a shift from treating every patient with the same cancer using similar medicines towards designing treatments based on the unique genetic characteristics of an individual patient's tumour.
The important distinction: These are not ordinary preventive vaccines like those used against COVID-19 or HPV. They are therapeutic vaccines designed to train the patient's immune system to recognise and attack cancer cells.
1. How personalised cancer vaccines work
The treatment generally involves four stages:
Tumour analysis: A sample of the patient's tumour is genetically analysed.
Identification: Scientists identify mutations that produce unusual proteins called neoantigens.
Vaccine development: An individualised vaccine is designed to teach the immune system to recognise these tumour-specific targets.
Immune activation: The vaccine stimulates T cells to recognise and attack cancer cells carrying those targets.
Some vaccines use mRNA technology, while others use peptides or different biological platforms.
2. Important advances across different cancers
Melanoma (skin cancer)
An October 2026 Phase III report found that combining a personalised mRNA vaccine, intismeran autogene (V940), with pembrolizumab reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. This is a significant advance for patients with high-risk melanoma following surgery.
Pancreatic cancer
Individualised mRNA vaccines have produced encouraging immune responses. A 2025 follow-up study found that patients who developed vaccine-induced T-cell responses had longer recurrence-free survival. Further studies are investigating whether these results can translate into reliable survival benefits.
Colorectal cancer
Researchers are investigating vaccines targeting KRAS mutations and other tumour-specific antigens. Early studies involving pancreatic and colorectal cancer patients have demonstrated promising immune responses, but larger trials are needed.
Lung cancer
Personalised mRNA vaccines are being investigated alongside immunotherapy. Clinical trials are evaluating whether they can reduce recurrence and improve outcomes in selected patients with non-small-cell lung cancer.
Blood cancers
Major progress is also coming from CAR-T cell therapy, bispecific antibodies and other immune-based treatments. These are different from personalised cancer vaccines, but they use the immune system to target malignant cells.
Liver cancer
Research is investigating personalised neoantigen vaccines and combinations with immune checkpoint inhibitors. These remain investigational approaches rather than established vaccine treatments.
3. Other important technologies transforming cancer treatment
Personalised vaccines are only one part of a much wider revolution in oncology.
Technology | How it helps |
|---|---|
mRNA vaccines | Teach immune cells to recognise tumour-specific targets |
CAR-T therapy | Reprograms a patient's immune cells to attack cancer |
Immunotherapy | Removes biological barriers that prevent immune cells attacking tumours |
Targeted therapy | Attacks specific molecular abnormalities in cancer cells |
Liquid biopsy | Detects tumour-related DNA in blood and helps monitor disease |
Precision medicine | Selects treatment based on the molecular profile of a tumour |
4. Does this mean cancer can now be cured?
Not yet. It is important to distinguish between scientific progress and established clinical treatment.
The current evidence suggests:
Some personalised vaccines can stimulate powerful and long-lasting immune responses.
Certain combinations with immunotherapy can reduce cancer recurrence.
Some patients may experience prolonged periods without detectable cancer.
Evidence of improved overall survival is still developing for most vaccine approaches.
A 2025 review in Nature Reviews Cancer identified early clinical efficacy, particularly in patients treated at earlier stages and in combination with immune checkpoint inhibitors.
5. What could happen over the next five years?
The major research priorities are likely to include:
Developing vaccines more quickly and reducing manufacturing costs.
Combining personalised vaccines with chemotherapy and immunotherapy.
Identifying patients most likely to benefit.
Preventing cancer recurrence after surgery.
Extending successful approaches to pancreatic, colorectal, lung and other cancers.
6. Important research references
For further scientific reading:
AACR – Personalised melanoma mRNA vaccine Phase III results (October 2026).
Memorial Sloan Kettering – Personalised pancreatic cancer vaccine research.
Nature Reviews Cancer – Recent advances in therapeutic cancer vaccines.
National Cancer Institute – Neoantigen vaccines and pancreatic cancer.
My overall assessment: We are entering an important new era in cancer medicine. Instead of relying exclusively on surgery, chemotherapy and radiation, medicine is increasingly learning how to use the patient's own immune system to identify and fight cancer.
However, personalised cancer vaccines are not yet approved standard treatments for all these cancer types, and patients should not delay established treatment in expectation of a vaccine.
The most exciting possibility is that cancer treatment could increasingly become personalised, mutation-specific and directed towards preventing recurrence rather than simply controlling an existing tumour.
No comments:
Post a Comment